Stay updated with breaking news from Gamida Cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gamida Cell (GMDA) and Inhibikase Therapeutics (IKT) are two publicly traded equities with low current valuations and significant upside.
Gamida Cell has a key FDA approval pending which could shift the trajectory of the company and the stock. Click here for a full investment analysis.
Here are few names that would make logical acquisition targets for larger players.
GMDA earnings call for the period ending June 30, 2022.
(RTTNews) - Gamida Cell Ltd. (GMDA), on Monday, announced that the U.S. Food and Drug Administration or FDA has accepted for filing the company's ...